None
Quote | Gritstone Oncology Inc. (NASDAQ:GRTS)
Last: | $0.5762 |
---|---|
Change Percent: | 0.84% |
Open: | $0.56 |
Close: | $0.5714 |
High: | $0.577 |
Low: | $0.555 |
Volume: | 271,739 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Gritstone Oncology Inc. (NASDAQ:GRTS)
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 22, 2024) - Faruqi & Faruqi, LLP, a leading national ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 16, 2024) - Faruqi & Faruqi, LLP, a leading national ...
Message Board Posts | Gritstone Oncology Inc. (NASDAQ:GRTS)
Subject | By | Source | When |
---|---|---|---|
AACR PR https://www.globenewswire.com/news-release/2023/04/17/2647754/0/en/Grits | jondoeuk | investorshub | 04/17/2023 8:03:02 PM |
Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:22 AM |
Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:21 AM |
Holy Fuck...Still just me! | Little Run | investorshub | 12/21/2022 2:25:03 AM |
znewcar1: $GRTS 26% v6,19M C3.92 f83,4M H4.05 ML2.49 | znewcar1 | investorshangout | 12/15/2022 12:55:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...